Previous 10 | Next 10 |
Overview of Products AcelRx has two products, Dsuvia and Zalviso. Dsuvia comes in the form of a sublingual tablet to be dissolved under the tongue, containing 30 micrograms of sufentanil. AcelRx has created a proprietary noninvasive delivery method through a one-time use, disposable applic...
AcelRx ( ACRX ) is newly arrived at the danger zone where it is attempting to market a newly FDA approved therapy for acute pain. I am dubious that it will succeed for the benefit of current shareholders on any near term time schedule. This article explains my thinking on the prospects and pit...
AcelRx ( ACRX ) is newly arrived at the danger zone where it is attempting to market a newly FDA approved therapy for acute pain. I am dubious that it will succeed for the benefit of current shareholders on any near term time schedule. This article explains my thinking on the prospects and pit...
REDWOOD CITY, Calif. , July 1, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Company has...
REDWOOD CITY, Calif. , June 3, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of a $25...
Last week, on Wednesday, May 8, AcelRx (NASDAQ: ACRX ) reported its financial results from the first quarter of 2019 . Though there has not been a huge amount of news to report since the company's last business update in March , it nevertheless appears that AcelRx is moving steadily along w...
Seanergy Maritime Holdings (NASDAQ: SHIP ) -48% on pricing stock offering. More news on: Seanergy Maritime Holdings Corp., Stamps.com Inc., Mer Telemanagement Solutions Ltd., Stocks on the move, Read more ...
AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2019 Earnings Conference Call May 08, 2019 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Chief Medical Officer Conference Call Participants Dan Busby - R...
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q1 GAAP EPS of -$0.17 beats by $0.05 . Revenue of $0.3M (-11.8% Y/Y) misses by $0.46M . Shares +1.1% . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,
REDWOOD CITY, Calif. , May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...